{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063955","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.570916+00:00","generated_at":"2026-05-22T13:10:45.789003+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit","bullets":["Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.","Cash $1.2B including $500M financing; runway into 2028.","First patient dosed for BEAM-301 in GSDIa; IND cleared for BEAM-302 in AATD.","BEAM-101 updated data accepted at EHA June 2025; aim to dose 30 SCD patients by mid-2025.","BEAM-302 fourth cohort dosing started; further data expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063955","json":"https://secwatch.observer/filing/0000950170-25-063955.json","markdown":"https://secwatch.observer/filing/0000950170-25-063955.md","text":"https://secwatch.observer/filing/0000950170-25-063955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/0000950170-25-063955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/beam-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:10:45.789003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}